[go: up one dir, main page]

MX2022004873A - Polipeptidos de tgf-?. - Google Patents

Polipeptidos de tgf-?.

Info

Publication number
MX2022004873A
MX2022004873A MX2022004873A MX2022004873A MX2022004873A MX 2022004873 A MX2022004873 A MX 2022004873A MX 2022004873 A MX2022004873 A MX 2022004873A MX 2022004873 A MX2022004873 A MX 2022004873A MX 2022004873 A MX2022004873 A MX 2022004873A
Authority
MX
Mexico
Prior art keywords
constructs
complexes
tgf
polypeptides
preparing
Prior art date
Application number
MX2022004873A
Other languages
English (en)
Inventor
Rodolfo J Chaparro
John F Ross
Iii Ronald D Seidel
Chee Meng Low
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of MX2022004873A publication Critical patent/MX2022004873A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona construcciones y complejos del factor de crecimiento transformante beta (TGF-ß) que son útiles, por ejemplo, en el tratamiento terapéutico de enfermedades que incluyen enfermedades autoinmunitarias. También se describen ácidos nucleicos que codifican las construcciones y complejos, y métodos para preparar las construcciones y complejos en sistemas de expresión basados en células.
MX2022004873A 2019-10-23 2020-10-22 Polipeptidos de tgf-?. MX2022004873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962925227P 2019-10-23 2019-10-23
PCT/US2020/056937 WO2021081258A1 (en) 2019-10-23 2020-10-22 TGF-β POLYPEPTIDES

Publications (1)

Publication Number Publication Date
MX2022004873A true MX2022004873A (es) 2022-05-13

Family

ID=75620850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004873A MX2022004873A (es) 2019-10-23 2020-10-22 Polipeptidos de tgf-?.

Country Status (12)

Country Link
US (3) US11692018B2 (es)
EP (2) EP4034170B1 (es)
JP (2) JP7756638B2 (es)
KR (1) KR20220087491A (es)
CN (1) CN114728072A (es)
AU (1) AU2020372413A1 (es)
BR (2) BR122023021925A2 (es)
CA (1) CA3155510A1 (es)
IL (1) IL292253A (es)
MX (1) MX2022004873A (es)
TW (1) TW202130655A (es)
WO (1) WO2021081258A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7756638B2 (ja) 2019-10-23 2025-10-20 キュー バイオファーマ，インコーポレーテッド ＴＧＦ－βポリペプチド
WO2022047220A1 (en) * 2020-08-27 2022-03-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof
EP4346889A4 (en) * 2021-05-26 2025-04-30 Cue Biopharma, Inc. Antigen-presenting polypeptide complexes and methods of using them
JP2024096518A (ja) * 2023-01-03 2024-07-16 エフビーデー バイオロジクス リミテッド 操作されたｔｇｆｂｒｉｉバリアント及びその使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
US20110165623A1 (en) 2004-01-06 2011-07-07 The Government Of The U.S. As Represented By The Secretary, Dept. Of Health & Human Services Compositions and Methods for the High Efficiency Expression of the Transforming Growth Factor-Beta Supergene Family
PT1850873T (pt) 2005-02-08 2019-02-19 Genzyme Corp Anticorpos contra tgfbeta
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
KR101558642B1 (ko) 2009-02-24 2015-10-12 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드
PL2542590T5 (pl) * 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
AU2014377106B2 (en) 2014-01-08 2019-10-03 Jiangsu Hengrui Medicine Co., Ltd. IL-15 heterodimeric protein and uses thereof
WO2016004383A1 (en) 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
JP6631865B2 (ja) 2014-08-11 2020-01-15 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
AU2016303485A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
WO2017151818A2 (en) 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP3856764A4 (en) * 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
JP7756638B2 (ja) * 2019-10-23 2025-10-20 キュー バイオファーマ，インコーポレーテッド ＴＧＦ－βポリペプチド

Also Published As

Publication number Publication date
WO2021081258A1 (en) 2021-04-29
EP4034170A1 (en) 2022-08-03
JP7756638B2 (ja) 2025-10-20
US11692018B2 (en) 2023-07-04
TW202130655A (zh) 2021-08-16
KR20220087491A (ko) 2022-06-24
CA3155510A1 (en) 2021-04-29
US20250206794A1 (en) 2025-06-26
JP2025160224A (ja) 2025-10-22
CN114728072A (zh) 2022-07-08
BR122023021925A2 (pt) 2024-02-27
EP4691566A2 (en) 2026-02-11
EP4034170A4 (en) 2023-06-07
AU2020372413A1 (en) 2022-06-09
JP2023500066A (ja) 2023-01-04
US20220372093A1 (en) 2022-11-24
US12528850B2 (en) 2026-01-20
US20230416322A1 (en) 2023-12-28
EP4034170B1 (en) 2026-02-11
IL292253A (en) 2022-06-01
BR112022007749A2 (pt) 2022-07-05

Similar Documents

Publication Publication Date Title
MX2022004873A (es) Polipeptidos de tgf-?.
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
CL2021002094A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153)
MX420412B (es) Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr.
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MY185845A (en) Icos binding proteins
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
MX2017015467A (es) Metodos y composiciones para inhibir la interaccion de menina con proteinas de mll.
BR112022008214A2 (pt) Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina
BR112017018975A2 (pt) proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
MX2021009035A (es) Composiciones y metodos para producir productos alimenticios con proteina animal recombinante.
BR112018074941A2 (pt) combinações farmacêuticas
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
MX2024003275A (es) Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas.
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
CL2019000846A1 (es) Proteína terapéutica.
CO2022002808A2 (es) Proteínas de fusión nkg2d y sus usos
BR112021011595A2 (pt) Proteína biespecífica
CL2020000482A1 (es) Composición para la estimulación ovárica controlada.